PART I OVERVIEW We are a commercial-stage pharmaceutical company that primarily focuses on the selling and marketing of U.S. Food and Drug Administration (FDA) approved prescription pharmaceutical products for the treatment of dermatological conditions. Our current product portfolio includes eight FDA-approved prescription drugs for dermatological conditions that are marketed in the U.S. We acquire rights to products and product candidates by licensing or otherwise acquiring an ownership interes...
Q2 FY2026 — expected 2026-09-16
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-03-26 | 2025-12-31 | 0001104659-26-034629 | EDGAR | 69K words |
| 2025-03-27 | 2024-12-31 | 0001410578-25-000490 | EDGAR | — |
| 2024-03-29 | 2023-12-31 | 0001410578-24-000347 | EDGAR | — |
| 2023-03-31 | 2022-12-31 | 0001410578-23-000485 | EDGAR | — |
| 2022-03-28 | 2021-12-31 | 0001410578-22-000558 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2025-11-12 | 2025-09-30 | 0001104659-25-110457 | EDGAR | 22K words |
| 2025-08-12 | 2025-06-30 | 0001410578-25-001703 | EDGAR | — |
| 2025-05-15 | 2025-03-31 | 0001410578-25-001296 | EDGAR | — |
| 2024-11-12 | 2024-09-30 | 0001410578-24-001877 | EDGAR | — |
| 2024-08-13 | 2024-06-30 | 0001410578-24-001326 | EDGAR | — |
| 2024-05-14 | 2024-03-31 | 0001410578-24-000817 | EDGAR | — |
| 2023-11-13 | 2023-09-30 | 0001410578-23-002335 | EDGAR | — |
| 2023-08-10 | 2023-06-30 | 0001410578-23-001702 | EDGAR | — |
| 2023-05-22 | 2023-03-31 | 0001410578-23-001327 | EDGAR | — |
| 2022-11-10 | 2022-09-30 | 0001410578-22-003162 | EDGAR | — |
| 2022-08-09 | 2022-06-30 | 0001410578-22-002183 | EDGAR | — |
| 2022-05-10 | 2022-03-31 | 0001410578-22-001266 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-03-25 | 0001104659-26-034506 | EDGAR | 4K words |
| 2025-11-12 | 0001104659-25-110344 | EDGAR | — |
| 2025-09-26 | 0001104659-25-093891 | EDGAR | — |
| 2025-08-28 | 0001104659-25-084879 | EDGAR | — |
| 2025-08-12 | 0001104659-25-076825 | EDGAR | — |
| 2025-07-14 | 0001104659-25-067767 | EDGAR | — |
| 2025-06-26 | 0001104659-25-063032 | EDGAR | — |
| 2025-06-24 | 0001104659-25-061956 | EDGAR | — |
| 2025-05-14 | 0001104659-25-048502 | EDGAR | — |
| 2025-04-03 | 0001104659-25-031463 | EDGAR | — |
74 total filings indexed. 47 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001867066 |
| Ticker | DERM |
| Exchange | Nasdaq |
| SIC | 2834: Pharmaceutical Preparations |
| Incorporated | DE |
| Website | https://www.jmcderm.com |
| Listed | 2021-11-12 |
This is a static snapshot. For live, structured JSON with cryptographic provenance chain:
MCP (recommended for AI): claude mcp add origin --transport http https://origin.rootz.global/mcp
Try it — paste this into your AI:
Works in ChatGPT, Claude, Gemini, or any AI. Free, structured, cryptographically signed — ~500 tokens vs 130,000 scraping an IR site.
claude mcp add origin --transport http https://origin.rootz.global/mcpGET https://origin.rootz.global/api/company/DERM (~200 tokens, structured JSON with cryptographic provenance)